Allergan has released a statement confirming that it is in preliminary friendly discussions regarding a potential business combination transaction with Pfizer. They note that no agreement has been reached and there can be no certainty that these discussions will lead to a transaction, nor as to the terms of a potential transaction.
“Under any potential scenario with Pfizer, Allergan will remain committed to complete the proposed divestment of its global generics business to Teva Pharmaceutical Industries and expects the generics divestiture transaction to close in the first quarter of 2016,” according to the company’s news release.
